THE COUNCIL OF THE QUEENSLAND INSTITUTE OF MEDICAL RESEARCH

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

T Cells and Pembrolizumab for Recurrent and Newly Diagnosed Glioblastoma

Phase 1

Recruiting

Conditions: Glioblastoma Multiforme
Astrocytoma, Grade IV

Interventions: Biological: Allogeneic cytomegalovirus-specific T cells
Drug: Pembrolizumab

First Posted Date: 2023-12-06

Last Posted Date: 2024-05-31

Lead Sponsor: Queensland Institute of Medical Research

Target Recruit Count: 58

Registration Number: NCT06157541

Locations: 🇦🇺
Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
🇦🇺
Newro Foundation, Bowen Hills, Queensland, Australia
🇦🇺
Royal Brisbane and Women's Hospital, Herston, Queensland, Australia

and more 1 locations

Epstein-Barr Virus (EBV)-Specific T Cells as Therapy for Relapsed/Refractory EBV-positive Lymphomas

Phase 1

Completed

Conditions: Lymphoma

Interventions: Biological: Autologous AdE1- Latent Membrane Protein CTLs

First Posted Date: 2008-10-24

Last Posted Date: 2012-05-22

Lead Sponsor: Queensland Institute of Medical Research

Target Recruit Count: 8

Registration Number: NCT00779337

Locations: 🇦🇺
Princess Alexandra Hospital, Brisbane, Queensland, Australia

The Prevalence of Rheumatic Heart Disease in School Children in Fiji

Conditions: Rheumatic Heart Disease

First Posted Date: 2008-10-24

Last Posted Date: 2008-10-24

Lead Sponsor: Queensland Institute of Medical Research

Target Recruit Count: 2000

Registration Number: NCT00779662

Prev
1
Next

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy